VectorY Therapeutics, a Dutch biotech developing vectorized antibody approaches for neurodegenerative diseases, has named Sander van Deventer, co-founder and formerly chief technology officer, as chief executive.
Dr van Deventer, who has 25 years of experience in drug development and a longstanding track record in antibody and gene therapy development, succeeds Alexander Vos, who led the company during the start-up phase.
"The potential to transform the therapeutic landscape in neurodegenerative diseases"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze